Not a term used in reporting clinical trial data. The use of the term in the report is just linguistic. In saying that, this does not stop a scientific commentary on the data to use the term if for example the data somewhat stands. Medical/scientific community always look at the numbers. Remember, this is an investor report not a scientific report ... like I say in this case, "we are barking at the right tree"!
Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-29
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $443.6M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.3¢ | $1.189M | 3.864M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78803 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1155 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |